FinVoices

In this interview we have invited Jack Egelund Madsen, CEO of QNTM Labs ApS. QNTM Labs is a private equity backed, Denmark-based analytical laboratory providing research, development and regulatory compliance services for the Danish and broader European pharmaceutical market.Jack tells us about his background and the company's ambitious growth plans. Jack also elaborates on the market that QNTM Labs targets and the types of customers the company serves.  Additionally, Jack explains what makes QNTM unique and how it differentiates itself from competitors. Jack also discusses the intention to raise additional capital to support strong growth. Lastly, he shares the company’s biggest goal for 2025, which is to increase revenue fivefold. FinVoices is powered by Impala Nordic. The host for this episode is Vilhelm Ruhr, Analyst at Impala Nordic. Disclaimer** Nothing mentioned in the podcast constitutes a buy or sell recommendation. The episode was produced on behalf of the company. 

ZignSec, a leader in digital identity verification, continues to help businesses meet complex compliance demands. In this episode of Finvoices, CEO Glenn Mac Donald and Product Manager Sergei Sergejev discuss the company's advanced KYC (Know Your Customer) and KYB (Know Your Business) solutions. Glenn highlights ZignSec's growth strategy and recent client wins, as well as his views on the public offer that the company and its shareholders received recently. Regardless of the offer’s outcome, ZignSec remains focused on innovation and sustainable growth. Sergei shares insights on how AI is transforming their KYC/KYB products and how the company is meeting rising compliance needs in sectors like cryptocurrency. With strong positioning, ZignSec is poised to deliver scalable solutions and remain a key player in the compliance space. FinVoices is powered by Impala Nordic. The host for this episode is Aya Salar, Partner at Impala Nordic. Disclaimer** Nothing mentioned in the podcast constitutes a buy or sell recommendation. The episode was produced on behalf of the company. 

In this episode of FinVoices, we are joined by Christopher Steele, CEO of Tangiamo Touch Technology. Christopher shares valuable insights into Tangiamo's business strategy and their decision to expand into the iGaming market through the acquisition of TrustPlay.He highlights the unique solutions Tangiamo provides and explains what sets them apart from competitors. Furthermore, Christopher explores the potential for integrating TrustPlay's solutions with Tangiamo’s existing legacy products. In addition, we discuss the key drivers for future growth and outline the company’s strategic focus moving forward. Lastly, Christopher elaborates on the goals for 2025. FinVoices is powered by Impala Nordic. The host for this episode is Vilhelm Ruhr, Analyst at Impala Nordic. Disclaimer** Nothing mentioned in the podcast constitutes a buy or sell recommendation. The episode was produced on behalf of the company.  Impala Nordic and/or people behind Impala Nordic are guarantors in the company's ongoing rights issue. 

In this episode of FinVoices, we’re joined by Kristofer Cook, co-founder, chairman and Chief Business Development Officer at Carbiotix. Kristofer shares insights into his entrepreneurial background and the journey of building Carbiotix.  We explore NutraCycle, an upcycling service backed by a decade of prebiotic research. The conversation covers Carbiotix decision to focus on NutraCycle, early customer reactions, and market potential. We also discuss plans for licensing agreements, profitability projections, and the role of trade shows. Additionally, we touch on the company's financial standing, competition, and team expansion. The episode concludes with Kristofer’s and Carbiotix’ ambitious goals for 2025.  Time indication:0.22 – Background and introduction12.58 - The decision to focus on NutraCycle 18.06 - The progress of NutraCycle21.26 - The market potential and geographic focus 24.14 - Ambitions for the first licensing agreement 27.34 - Outlook on profitability 35.02 - The importance of trade shows 36.45 - The financial position 38.20 - The dialogue with investors 42.09 - The competition 43.50 - Thoughts about expanding the team 45.30 - Goal for 2025   FinVoices is powered by Impala Nordic. The host for this episode is Vilhelm Ruhr, Analyst at Impala Nordic. Disclaimer** Nothing mentioned in the podcast constitutes a buy or sell recommendation. The episode was produced on behalf of the company. 

I detta avsnitt av FinVoices välkomnar vi Karin Wehlin, VD för Diagonal Bio AB (publ). Karin berättar om hennes resa från att vara medgrundare av EQL Pharma till att leda Diagonal Bio. Vi tar reda på vad som lockade henne till Diagonal Bio och vilka erfarenheter hon tar med sig från både EQL Pharma och Respiratorius.I podden berättar Karin också om Diagonal Bios CE-märkta produkt LAMPlify® och deras planer för Panviral, samt utmaningar och möjligheter i den snabbväxande biotech- och medtech-sektorn. Karin ger sin syn på det nuvarande börs- och finansieringsklimatet för mindre bolag och diskuterar strategier för att säkra kapital och nå finansiella mål.FinVoices drivs av Impala Nordic. Programledare i avsnittet är Vilhelm Ruhr, analytiker på Impala Nordic. Disclaimer** Inget som sägs i podden är en köp- eller säljrekommendation. Avsnittet har gjorts på uppdrag av bolaget. Personer bakom Impala Nordic äger aktier i bolaget.

I detta avsnitt välkomnar vi Ulf Hannelius, VD för Diamyd Medical AB (publ). Han delar med sig av sin bakgrund inom molekylärbiologi och erfarenhet i bioteknikindustrin, samt ger en översikt över Diamyd Medical.Vi diskuterar nuvarande projekt och utveckling, inklusive framstegen i DIAGNODE-3-studien och betydelsen av FDA Fast Track-designation. Ulf förklarar också intralymfatiska immunterapins fördelar och ger en uppdatering på deras tillverkningsanläggning i Umeå. Ulf berör bolagets finansieringsstrategi, strategiska samarbeten och hur Diamyd Medical står ut inom typ 1-diabetesbehandlingar. Avslutningsvis svarar Ulf på lyssnarfrågor om bland annat börslistning, patientrekrytering i USA och framtida planer för Diamyd Medical.Tidsanvisning:03:11 Om Diamyd07:43 Immunterapi och GAD6510:50 Fas 3 studien 12:40 Fast Track Designation16:48 Interimsanalys20:24 Partnerskap23:17 Finansieringssituation28:30 Lyssnarfrågor   FinVoices drivs av Impala Nordic. Programledare i avsnittet är Aya Salar, partner på Impala Nordic. Disclaimer** Inget som sägs i podden är en köp- eller säljrekommendation. Avsnittet har gjorts på uppdrag av bolaget.

I dagens avsnitt av FinVoices får vi en unik inblick i OncoZenges framtagning av sin sugtablett, BupiZenge, med Christoph Nowak som är styrelseledamot på OncoZenge AB (publ).Christoph delar med sig av sin resa inom läkemedels- och forskningsbranschen där han bl.a. har en PhD i molekylär epidemiologi från Uppsala universitet. Han ger en insikt i sina tidigare roller vilka har lett honom till styrelsearbetet på OncoZenge. I avsnittet diskuteras de nuvarande behandlingsalternativ för oral mukosit och varför BupiZenge utgör ett betydelsefullt framsteg inom området. Vi utforskar också potentialen för patientupptag av BupiZenge på kort och lång sikt baserat på erfarenheter. Dessutom tar vi en närmare titt på Christoph Nowaks andra roller som Chief Medical- och Business Officer på Diamyd Medical AB (publ) och Melius Pharma. Avsnittet avslutas med en diskussion om Christophs investerarintresse och drivkrafter inom bolagsbyggande inom läkemedelsutveckling.FinVoices drivs av Impala Nordic. Programledare i avsnittet är Aya Salar, partner på Impala Nordic. Disclaimer** Inget som sägs i podden är en köp- eller säljrekommendation. Avsnittet har gjorts på uppdrag av bolaget.

In this episode, we delve into the innovative world of ZignSec AB (publ) with CEO Glenn Mac Donald. He shares his path to leading ZignSec and the company's mission to transform and simplify KYC and KYB processes. Mac Donald outlines how ZignSec navigates regulatory changes and technological advancements to maintain its leading position in the RegTech industry and to be "fast-followers." He also provides insights into the challenges encountered, strategies for future expansion, and upcoming initiatives aimed at globalizing ZignSec's operations. This discussion gives a glimpse into the strategic vision and dynamic leadership propelling ZignSec's progress in growing. Finally, Mac Donald shares his ambitions for ZignSec and the team's willingness to achieve shareholder value, where one of the long-term goals mentioned is to achieve 20 million euro in net revenue during 2027. FinVoices is powered by Impala Nordic. The host for this episode is Aya Salar, co-founder of Impala Nordic. Disclaimer** Nothing mentioned in the podcast constitutes a buy or sell recommendation. The episode was produced on behalf of the company.